Therapeutic potential of targeting the oncogenic SHP2 phosphatase

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is a key oncogenic phosphatase implicated in various cancers.
• Developing selective SHP2 inhibitors is crucial for anticancer and antileukemia therapies.

Purpose of the Study:

• To identify and characterize novel SHP2 inhibitors with potential therapeutic applications.
• To investigate the binding mechanism and cellular effects of a newly discovered inhibitor.

Main Methods:

• Structure-guided and fragment-based drug discovery approach.
• Biochemical assays to determine inhibitory concentration (IC50) and selectivity against other protein tyrosine phosphatases (PTPs).
• Cellular assays to assess inhibition of SHP2-dependent signaling pathways and antiproliferative activity.

Main Results:

• A novel hydroxyindole carboxylic acid-based inhibitor, 11a-1, was identified with an IC50 of 200 nM.
• 11a-1 demonstrated >5-fold selectivity against 20 mammalian PTPs.
• Structural studies revealed specific binding interactions within the SHP2 active site and β5-β6 loop.
• 11a-1 effectively attenuated SHP2-dependent signaling, blocked growth factor-mediated Erk1/2 and Akt activation, and showed antiproliferative activity in lung cancer, breast cancer, and leukemia cell lines.

Conclusions:

• The novel inhibitor 11a-1 exhibits potent and selective inhibition of SHP2.
• 11a-1 targets key cancer signaling pathways, demonstrating significant antiproliferative effects in preclinical cancer models.
• This hydroxyindole carboxylic acid derivative represents a promising lead compound for developing new anticancer and antileukemia drugs.